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Although randomised trials in metastatic gastric cancer have shown a survival benefit from chemotherapy, a significant proportion of
medical oncologists do not believe that it prolongs survival or improves quality of life, including those who routinely treat metastatic
gastric cancer. There was wide variation in what was considered to be ‘standard therapy’ and a statistically significant difference
between what medical oncologists consider ‘standard therapy’ and what they use in every day practice.
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Gastric cancer remains a major health challenge because of its
increasing incidence worldwide and its lethality. The outcome for
patients with metastatic gastric cancer (MGC) remains poor with
median survivals ranging from 5 to 12 months (Karpeh et al, 2001).
Enthusiasm for systemic chemotherapy has fluctuated as results
have emerged from several phase II and III studies with varying
and sometimes inconsistent results in terms of response rate and
overall survival. Thus, there is a possibility of significant practice
variation in the approach to patients with MGC, both in whether to
use systemic therapy and in the choice of regimen. To the authors’
knowledge, there is no data from any country that documents the
practice patterns and practice variation in the treatment of MGC.
The objective of this population-based study was to quantify the
current opinions and practice patterns of Canadian medical
oncologists with regards to the benefit of systemic therapy and
what systemic therapy would be considered standard in MGC.
MATERIALS AND METHODS
A two-page, 19-item survey was sent to all practicing medical
oncologists in Canada. The survey was designed by two medical
oncologists who routinely manage MGC; reviewed by two
independent oncology specialists for construct validity; and
revised accordingly. All responding medical oncologists answered
nine questions pertaining to their demographics, whether they
routinely manage patients with MGC, their perception of whether
chemotherapy prolongs survival or improves quality of life (QOL),
and what they considered ‘standard therapy’ in this disease.
Medical oncologists who routinely treat patients with MGC
answered 10 further questions about chemotherapy regimens
commonly used in ‘every day practice’ and their views on future
clinical trials in MGC. Since all Canadian cancer patients are seen
in a public health care system and the survey was sent to all
Canadian medical oncologists, the intent was to obtain population-
based results free from referral and selection bias. The mailing list
consisted of the names of medical oncologists obtained from the
membership lists of four voluntary medical organisations with the
expectation of capturing all medical oncologists. Responses were
anonymous. The first mailing was sent out on 5 March 2001 and a
second mailing was sent out to all nonresponders on 24 May 2001.
Data was analysed using the SAS-8.2 statistical software package
(SAS Institute, Inc., Cary, NC, USA). The w
2 test for significance for
categorical data was used. The Fischer exact test was used when the
numbers in the cells were less than 5. Statistical significance was
set a priori at Pp0.05 and all tests were two-tailed.
RESULTS
Of 425 surveys that were sent, 256 were returned for a 60%
response. Of these, 39 were not evaluated for reasons such as
retired or a paediatric practice. Thus, 217 respondents formed the
study cohort upon which subsequent analysis was based.
Of the 217 respondents, 121 (56%) indicated that they routinely
manage patients with MGC. The number of patients they treated
varied from 2 to 20 per year with the most frequent response being
five (23%) or 10 (18%) patients per year.
Use of chemotherapy
Of all respondents, 41% of all oncologists thought chemotherapy
prolonged survival in MGC and 59% felt that it improved QOL.
Medical oncologists who treat MGC were significantly more likely
to perceive a survival benefit (53 vs 27%, P¼0.0001) and QOL
benefit (72 vs 43%, Po0.0001), as shown in Table 1.
Type of chemotherapy
Treatment modalities considered ‘standard therapy’ by all medical
oncologists are shown in Table 2. The most common treatments
included epirubicin, cisplatin, 5-FU (ECF) and etoposide, leucov-
orin, 5-FU (ELF). Medical oncologists who treat MGC were
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lsignificantly more likely to respond ECF (31 vs 19%, P¼0.05) or
ELF (31 vs 17%, P¼0.01) than those who do not treat MGC and
less likely to respond ‘unsure’ (9 vs 31%, Po0.001) or ‘best
supportive care (BSC)’ (7 vs 15%, P¼0.05), also shown in Table 2.
There was a statistically significant difference between what
medical oncologists who routinely treat MGC considered ‘standard
therapy’ and what they most commonly use in ‘every day practice’,
as shown in Table 3. Most notably, more ELF and less ECF was
routinely used.
Clinical trial information
Clinical trials in MGC were considered high priority by 81% of
medical oncologists who routinely manage MGC with preference
given to phase III trial participation. Opinions regarding the
reference arm for future phase III trials varied with the most
common responses being ECF (34%), ELF (22%), and BSC (17%).
DISCUSSION
Despite significant research in gastric cancer, the overall prognosis
remains poor. Systemic therapy for MGC has evolved over the past
4 decades. Initially single agents such as 5-FU, doxorubicin,
mitomycin C and cisplatin were shown to have activity. This led to
the development of combination chemotherapy such as 5-FU,
doxorubicin and mitomycin C (FAM) and 5-FU, doxorubicin and
carmustine (FAB). Comparative studies of these combinations to
single agents did not show an improvement in RR or survival
(Cullinan et al 1985; Levi et al, 1986).
Potentially more effective combinations such as 5-FU, doxor-
ubicin and methotrexate (FAMTX), etoposide, doxorubicin, cispla-
tin (EAP), ELF and ECF were studied with varying response rates
(Klein, 1989; Preusser et al,1 9 8 9 ;F i n d l a yet al, 1994; di Bartolomeo
et al, 1995). The value of combination chemotherapy was again
questioned. In fact, in 1990, the Swedish Consensus Conference
stated, ‘The use of chemotherapy has no place in the routine care of
patients with advanced gastric cancer’ (Consensus Statement, 1990).
Owing to these emerging views, four randomised trials of
combination chemotherapy vs BSC were conducted. All showed
statistically significant improvement in survival with combination
therapy. These trials included a comparison of BSC to FAMTX
(median survival 3 vs 9 months) (Murad et al, 1993); 5FU,
epirubicin, methotrexate (FEMTX) (median survival 3.1 vs 12.3)
(Pyrhonen et al, 1995); 5-FU, leucovorin7etoposide (median
survival 5 vs 8 months) (Glimelius et al, 1997); and 5-FU,
leucovorin, and epirubicin (median survival 4 vs 47.5 months)
(Scheithauer et al, 1995). An improvement in QOL with
chemotherapy using the EORTC QLQ-30 version 1.0 (45%
prolonged or high QOL vs 20%, Po0.01), as well as physician’s
perception of improved QOL (55 vs 20%, P¼0.03) was shown
(Glimelius et al, 1997). Although these studies were small, used
different chemotherapy, and have some methodological limita-
tions, their results were consistent, with median survivals
increasing from 3–5 months with BSC to 8–12 months with
combination chemotherapy. Based on these studies, it is reason-
able to conclude that combination chemotherapy does offer a
survival benefit to patients with MGC.
If there is a benefit from chemotherapy, the obvious question is,
which combination is best? Three of the most notable comparative
trials show that FAMTX was superior to FAM (median survival 42
vs 29 weeks) (Wils et al, 1991); ECF was superior to FAMTX
(median survival 8.9 vs 5.7 months) (Webb et al, 1997); and neither
FAMTX nor ELF nor infusional 5-FU/cisplatin (FUP) were
superior (median survival 6.7 vs 7.2 vs 7.2 months) (Vanhoefer
et al, 2000). The QOL was assessed in the ECF vs FAMTX trial and
found to be equal with the exception of superior global QOL scores
with ECF at 24 weeks. Considering these three trials, one might
conclude that ECF is superior although it has not been directly
compared to ELF or FUP.
Despite randomised trials showing a survival benefit from
chemotherapy, this survey showed that less than half of all medical
oncologists believe that chemotherapy improves survival and just
over half believe that it improves QOL. Interestingly, only 53% of
medical oncologists who routinely manage MGC felt that
chemotherapy improved survival. This raises the question of
why these varying perceptions of benefit exist. This survey did not
address the reasons behind these differences. Some reasons may
include that medical oncologists do not feel the evidence is strong
enough, that the observed benefit does not meet their own
predefined threshold of benefit, that the studies were methodolo-
gically flawed or that patient numbers were too small. Perhaps the
studies referred to are not widely known or that the known
information is simply not put into clinical practice.
Table 1 Perceptions of chemotherapy on survival and quality of life in
metastatic gastric cancer
Treat MGC
(n¼118)
(%)
Do not treat
MGC (n¼94)
(%) P-value
All respondents
(n¼212)
a
(%)
Survival
Improves 53 27 0.0001 41
Unsure 18 34 0.007 25
Quality of life
Improves 72 43 o0.0001 59
Unsure 20 45 0.0001 31
aMissing data in five. MGC¼metastatic gastric cancer.
Table 2 Opinions on ‘standard therapy’ for metastatic gastric cancer
(MGC)
Treat MGC
(n¼120)
(%)
Do not treat
MGC (n¼94)
(%) P-value
All respondents
(n¼214)
a
(%)
ECF
b 31 19 0.05 26
ELF
c 31 17 0.01 25
5-FU/cisplatin
d 13 10 NS 11
BSC
e 7 15 0.05 10
Other
f 99 N S9
Unsure 9 31 o0.001 19
aMissing data in three.
bEpirubicin, cisplatin, 5-FU.
cEtoposide, leucovorin, 5-FU.
dInfusional 5-FU, cisplatin.
eBest supportive care.
fIncluded 5-FU, doxorubicin,
mitomycin C (FAM); 5-FU, doxorubicin, methotrexate (FAMTX); 5-FU, leucovorin.
NS¼not significant.
Table 3 ‘Standard therapy’ vs therapy used in ‘every day practice’ in
MGC by medical oncologists who treat MGC
Standard
therapy
(n¼120)
(%)
Therapy in every
day practice
(n¼118)
(%)
P-value*
(%)
ECF 31 27 0.0001
ELF 31 39 o0.0001
5-FU/cisplatin 13 16
Best supportive care 7 4 o0.0001
Other 9 15 o0.0001
Unsure 9 0
*P-value: the Fischer exact test. MGC¼metastatic gastric cancer.
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‘standard therapy’ for MGC. To help explain the variation seen in
this survey, one simply has to look at the literature. Based on the
improvement in survival with ECF over FAMTX, the Royal
Marsden Hospital concluded ‘ECF should be regarded as the
standard treatment in advanced esophagogastric cancer’ (Webb
et al, 1997). Given the comparable outcomes with ELF, FAMTX
and FUP, the EORTC concluded that ‘based on their low activity in
advanced gastric cancer, none of these regimens can be regarded
as standard treatment’ (Vanhoefer et al, 2000). The National
Comprehensive Cancer Network has proposed 5-FU-based,
cisplatin-based, taxane-based or irinotecan-based combinations
as acceptable choices (National Comprehensive Cancer Network,
2003). In an editorial, Ajani points out that ‘5-FU alone or with S-1
is standard therapy in Japan, but 5-FU plus cisplatin is also used
frequently. 5-Fluorouracil plus cisplatin is frequently used in
Korea, Japan, many South American countries and many European
countries. The ECF is considered as the standard in a few European
countries and perhaps in Canada’ (Ajani, 2000). Since this survey,
two other randomised phase III studies have been published
showing no survival benefit of FUP over 5-FU alone (Ohtsu et al,
2003) or protracted venous infusion 5-FU, cisplatin, and mitomy-
cin over ECF (Ross et al, 2002). Based on these results, the
Japanese Clinical Oncology Group is using 5-FU alone as their
reference arm and the Royal Marsden Hospital continues to use
ECF as their reference arm for future studies.
This survey also showed a difference between what medical
oncologists considered ‘standard therapy’ and what they used most
commonly in ‘every day practice’. This was an unanticipated result
and the survey did not address the reasons for this difference.
Perhaps certain chemotherapy regimens are felt to be too toxic or
complex or once again, that the known information is simply not
put into clinical practice.
Metastatic gastric cancer is a global disease with a poor
prognosis. New therapeutic regimens must reproducibly produce
median survivals of greater than 12 months to be convincingly
superior to the older regimens and data must come from well-
designed studies. Alternatively, given that there is no consensus on
the reference arm for future phase III trials some would argue that
comparative studies be put on hold with efforts instead
concentrated on new drug development and novel approaches.
The findings of this study suggest that once significant break-
throughs are made, the dissemination of such information is of
importance and should not be overlooked.
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